[
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Topped the Market Today",
    "summary": "Zepbound could benefit handsomely if an apparently planned government program is implemented.",
    "url": "https://finnhub.io/api/news?id=db418be09260d8bd50990bd481907666b1eb2dcacedd668e4dfd72aabdeae07d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754088180,
      "headline": "Why Eli Lilly Stock Topped the Market Today",
      "id": 136183148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zepbound could benefit handsomely if an apparently planned government program is implemented.",
      "url": "https://finnhub.io/api/news?id=db418be09260d8bd50990bd481907666b1eb2dcacedd668e4dfd72aabdeae07d"
    }
  },
  {
    "ts": null,
    "headline": "Earnings, Fed commentary, consumer credit: What to Watch",
    "summary": "Market Domination Overtime host Josh Lipton takes a look at the top stories for investors to watch this weekend, starting Saturday, Aug. 2, and next week, starting Monday, Aug. 4. This Saturday, Berkshire Hathaway (BRK-B, BRK-A) is releasing quarterly results. Next week, a host of quarterly earnings will be posted: Monday: Palantir (PLTR) and Hims & Hers (HIMS) Tuesday: Pfizer (PFE), Advanced Micro Devices (AMD), and Rivian (RIVN) Wednesday: Novo Nordisk (NVO), Disney (DIS), McDonald's (MCD), Uber (UBER), and Lyft (LYFT) Thursday: Eli Lilly (LLY), Toyota (TM), and Warner Bros. Discovery (WBD) We will be getting fresh Federal Reserve commentary on Thursday when Atlanta Fed President Raphael Bostic delivers remarks. This comes Consumer credit data for the month of June will be posted in the afternoon. Economists are expecting an increase from the prior month. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=04dd52ad3909f8fce86a767476ce0b4ef78f2de3765240d229258feabc612248",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754086503,
      "headline": "Earnings, Fed commentary, consumer credit: What to Watch",
      "id": 136180619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Market Domination Overtime host Josh Lipton takes a look at the top stories for investors to watch this weekend, starting Saturday, Aug. 2, and next week, starting Monday, Aug. 4. This Saturday, Berkshire Hathaway (BRK-B, BRK-A) is releasing quarterly results. Next week, a host of quarterly earnings will be posted: Monday: Palantir (PLTR) and Hims & Hers (HIMS) Tuesday: Pfizer (PFE), Advanced Micro Devices (AMD), and Rivian (RIVN) Wednesday: Novo Nordisk (NVO), Disney (DIS), McDonald's (MCD), Uber (UBER), and Lyft (LYFT) Thursday: Eli Lilly (LLY), Toyota (TM), and Warner Bros. Discovery (WBD) We will be getting fresh Federal Reserve commentary on Thursday when Atlanta Fed President Raphael Bostic delivers remarks. This comes Consumer credit data for the month of June will be posted in the afternoon. Economists are expecting an increase from the prior month. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=04dd52ad3909f8fce86a767476ce0b4ef78f2de3765240d229258feabc612248"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Week Ahead: Caterpillar, Palantir And Black Hat Week",
    "summary": "A tough week for the stock market left a scattering of top stocks near buy points. Palantir, Disney, Caterpillar are among those due to report.",
    "url": "https://finnhub.io/api/news?id=47d1ddd8ad4dd8e948b4e795dcfb624a9bb7e841766b08dd47b9823d5d747aad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754085529,
      "headline": "Stock Market Week Ahead: Caterpillar, Palantir And Black Hat Week",
      "id": 136183151,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A tough week for the stock market left a scattering of top stocks near buy points. Palantir, Disney, Caterpillar are among those due to report.",
      "url": "https://finnhub.io/api/news?id=47d1ddd8ad4dd8e948b4e795dcfb624a9bb7e841766b08dd47b9823d5d747aad"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Posts Weekly Decline as Payrolls Data Misses Expectations",
    "summary": "The Standard & Poor's 500 index fell 2.4% this week as payrolls data missed forecasts. The index",
    "url": "https://finnhub.io/api/news?id=a3a48df4a0cc4ae6886f67597e100a86cdff50d58cdd1b8decf219039021078f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754081292,
      "headline": "S&P 500 Posts Weekly Decline as Payrolls Data Misses Expectations",
      "id": 136183152,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Standard & Poor's 500 index fell 2.4% this week as payrolls data missed forecasts. The index",
      "url": "https://finnhub.io/api/news?id=a3a48df4a0cc4ae6886f67597e100a86cdff50d58cdd1b8decf219039021078f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Reports Results From SURPASS-CVOT Study: Mounjaro's Impact Analyzed",
    "summary": "Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive announcements, the company's share price fell by 4.62% over the past month. This decline aligns with broader market trends, including the sharp downturn in major indices triggered by renewed tariff tensions and a weak jobs report. In contrast, Lilly's progress in diabetes and Alzheimer's treatments...",
    "url": "https://finnhub.io/api/news?id=0b53835e2db32e482232b9d1b5490145fae24f9b17cdc04b2d87331cd89ca14a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754070470,
      "headline": "Eli Lilly (LLY) Reports Results From SURPASS-CVOT Study: Mounjaro's Impact Analyzed",
      "id": 136183153,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive announcements, the company's share price fell by 4.62% over the past month. This decline aligns with broader market trends, including the sharp downturn in major indices triggered by renewed tariff tensions and a weak jobs report. In contrast, Lilly's progress in diabetes and Alzheimer's treatments...",
      "url": "https://finnhub.io/api/news?id=0b53835e2db32e482232b9d1b5490145fae24f9b17cdc04b2d87331cd89ca14a"
    }
  },
  {
    "ts": null,
    "headline": "Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem.",
    "summary": "The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.",
    "url": "https://finnhub.io/api/news?id=0091d0a42461cde75f261916ee180036c8aed136fc5e33728f0cb5e3eee1cddd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754069700,
      "headline": "Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem.",
      "id": 136183154,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.",
      "url": "https://finnhub.io/api/news?id=0091d0a42461cde75f261916ee180036c8aed136fc5e33728f0cb5e3eee1cddd"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Rapidly Decreasing Importance Of Eylea",
    "summary": "Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.",
    "url": "https://finnhub.io/api/news?id=d5cb9bd425d2606813dd3ada36d7b958c73bc3ff94a8ecae486367615b9a48b0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754064332,
      "headline": "Regeneron: Rapidly Decreasing Importance Of Eylea",
      "id": 136178284,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153982109/image_2153982109.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.",
      "url": "https://finnhub.io/api/news?id=d5cb9bd425d2606813dd3ada36d7b958c73bc3ff94a8ecae486367615b9a48b0"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to watch next week: BP, Diageo, Disney, Uber and WPP",
    "summary": "Earnings preview of key companies reporting next week and what to look out for.",
    "url": "https://finnhub.io/api/news?id=8f6d19339cc79d3a0f38348d569e04f911548737030e6518d7b7f19b9bc82e26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754062721,
      "headline": "Stocks to watch next week: BP, Diageo, Disney, Uber and WPP",
      "id": 136165211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Earnings preview of key companies reporting next week and what to look out for.",
      "url": "https://finnhub.io/api/news?id=8f6d19339cc79d3a0f38348d569e04f911548737030e6518d7b7f19b9bc82e26"
    }
  },
  {
    "ts": null,
    "headline": "Stock Losses Extend on Tariffs, Swiss Franc Drops: Markets Wrap",
    "summary": "(Bloomberg) -- A global stock selloff extended to a sixth day - the longest losing streak since September 2023 - as President Donald Trump boosted tariffs across the world and two days of solid megacap tech earnings failed to lift sentiment.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial RebuildSan Francisco in Talks Wit",
    "url": "https://finnhub.io/api/news?id=8999e4b029e23177973986e041c5070c8ff614e9174833075963d538a9ba9015",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754027870,
      "headline": "Stock Losses Extend on Tariffs, Swiss Franc Drops: Markets Wrap",
      "id": 136160730,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- A global stock selloff extended to a sixth day - the longest losing streak since September 2023 - as President Donald Trump boosted tariffs across the world and two days of solid megacap tech earnings failed to lift sentiment.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial RebuildSan Francisco in Talks Wit",
      "url": "https://finnhub.io/api/news?id=8999e4b029e23177973986e041c5070c8ff614e9174833075963d538a9ba9015"
    }
  },
  {
    "ts": null,
    "headline": "Trim Your AI Stocks And Buy Eli Lilly",
    "summary": "AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click for my LLY stock update.",
    "url": "https://finnhub.io/api/news?id=8720f062a519f38c9a63ab1ca038f5ac886077cab33af49ed0850682d8bb1de9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754061499,
      "headline": "Trim Your AI Stocks And Buy Eli Lilly",
      "id": 136175607,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/831679804/image_831679804.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click for my LLY stock update.",
      "url": "https://finnhub.io/api/news?id=8720f062a519f38c9a63ab1ca038f5ac886077cab33af49ed0850682d8bb1de9"
    }
  },
  {
    "ts": null,
    "headline": "Tariffs and Economic Jitters Hammer Stocks",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) today is down -1.60%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.77%. September E-mini S&P futures (ESU25 ) are down -1.67%, and September E-mini Nasdaq futures...",
    "url": "https://finnhub.io/api/news?id=955177275da641542585516c5995b6ab376b4f59f1d3951360d78fc8de6b13f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754061459,
      "headline": "Tariffs and Economic Jitters Hammer Stocks",
      "id": 136165100,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The S&P 500 Index ($SPX ) (SPY ) today is down -1.60%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.77%. September E-mini S&P futures (ESU25 ) are down -1.67%, and September E-mini Nasdaq futures...",
      "url": "https://finnhub.io/api/news?id=955177275da641542585516c5995b6ab376b4f59f1d3951360d78fc8de6b13f8"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Slump on Tariffs and Weak US Job Growth",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures...",
    "url": "https://finnhub.io/api/news?id=d0b5022825f76d5d648cea23db874fa76af76372001e1c23b4f4f8535494e264",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754057412,
      "headline": "Stocks Slump on Tariffs and Weak US Job Growth",
      "id": 136164945,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures...",
      "url": "https://finnhub.io/api/news?id=d0b5022825f76d5d648cea23db874fa76af76372001e1c23b4f4f8535494e264"
    }
  },
  {
    "ts": null,
    "headline": "Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings",
    "summary": "PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.",
    "url": "https://finnhub.io/api/news?id=bd2348076c139f70484ae35e21067cfef1c5a501917f4279cd5024e209cee273",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754056860,
      "headline": "Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings",
      "id": 136165215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.",
      "url": "https://finnhub.io/api/news?id=bd2348076c139f70484ae35e21067cfef1c5a501917f4279cd5024e209cee273"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double",
    "summary": "These pharmaceutical giants are well worth a second look.",
    "url": "https://finnhub.io/api/news?id=6676740bb5f45546f4ecd3c7c9c472208a138515f0e883926f0f512ffffb1a95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754056800,
      "headline": "3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double",
      "id": 136165216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These pharmaceutical giants are well worth a second look.",
      "url": "https://finnhub.io/api/news?id=6676740bb5f45546f4ecd3c7c9c472208a138515f0e883926f0f512ffffb1a95"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market News for Aug 1, 2025",
    "summary": "Wall Street closed lower on Thursday, pulled down by health care and real estate stocks.",
    "url": "https://finnhub.io/api/news?id=2267747cd146b2a165688a5bdb3ad892f7510b4c230e9c8d0ecfb7b3e3d833e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754055000,
      "headline": "Stock Market News for Aug 1, 2025",
      "id": 136165217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Wall Street closed lower on Thursday, pulled down by health care and real estate stocks.",
      "url": "https://finnhub.io/api/news?id=2267747cd146b2a165688a5bdb3ad892f7510b4c230e9c8d0ecfb7b3e3d833e5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: The Best Growth Prospects Come At A Price",
    "summary": "Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs suggest caution. Click here to read.",
    "url": "https://finnhub.io/api/news?id=a103bea0a7385c6e454f3842fe118b732b1d0bb2629309292d9913da91a5cfde",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754052076,
      "headline": "Eli Lilly: The Best Growth Prospects Come At A Price",
      "id": 136167292,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs suggest caution. Click here to read.",
      "url": "https://finnhub.io/api/news?id=a103bea0a7385c6e454f3842fe118b732b1d0bb2629309292d9913da91a5cfde"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage",
    "summary": "Investing.com -- Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post reported that Medicare and Medicaid programs are planning to experiment with covering weight loss drugs.",
    "url": "https://finnhub.io/api/news?id=9e9ff092323b8c541c9031ee94ecd9454b54930a50ec8fc33dd58cbb61df87d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754051561,
      "headline": "Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage",
      "id": 136165218,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post reported that Medicare and Medicaid programs are planning to experiment with covering weight loss drugs.",
      "url": "https://finnhub.io/api/news?id=9e9ff092323b8c541c9031ee94ecd9454b54930a50ec8fc33dd58cbb61df87d0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed",
    "summary": "Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.",
    "url": "https://finnhub.io/api/news?id=e22182e31a15ea6c3ef03fe0df6aded18481a984f4c6c4644ff70b2ae65b589e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754048476,
      "headline": "Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed",
      "id": 136165219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.",
      "url": "https://finnhub.io/api/news?id=e22182e31a15ea6c3ef03fe0df6aded18481a984f4c6c4644ff70b2ae65b589e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares hit lowest level in over 3-years",
    "summary": "Investing.com -- Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.",
    "url": "https://finnhub.io/api/news?id=36c922be5fc627c7a5a9b4d783ceb4e1477b8826c9128c9c68363f3118f4f1cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754046952,
      "headline": "Novo Nordisk shares hit lowest level in over 3-years",
      "id": 136165220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.",
      "url": "https://finnhub.io/api/news?id=36c922be5fc627c7a5a9b4d783ceb4e1477b8826c9128c9c68363f3118f4f1cc"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus",
    "summary": "With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.",
    "url": "https://finnhub.io/api/news?id=25dd9c096cf792ce59ec238cbdaeeeb67cc7cdb50ac4be25ccd60fd34d09568b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754035200,
      "headline": "Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus",
      "id": 136165221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.",
      "url": "https://finnhub.io/api/news?id=25dd9c096cf792ce59ec238cbdaeeeb67cc7cdb50ac4be25ccd60fd34d09568b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: The Worst May Be Already Over (Earnings Preview)",
    "summary": "Eli Lilly stock is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Read the full earnings preview here.",
    "url": "https://finnhub.io/api/news?id=a889660edab9d8e2c127c12fae5128f27512e693e3627d5adaa3c25e6ec007e4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754035200,
      "headline": "Eli Lilly: The Worst May Be Already Over (Earnings Preview)",
      "id": 136164022,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/542007658/image_542007658.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly stock is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Read the full earnings preview here.",
      "url": "https://finnhub.io/api/news?id=a889660edab9d8e2c127c12fae5128f27512e693e3627d5adaa3c25e6ec007e4"
    }
  },
  {
    "ts": null,
    "headline": "Trump Demands Pharma Companies to Lower US Prices",
    "summary": "US President Donald Trump sent letters to 17 of the world's largest pharmaceutical companies demanding they charge the US what other countries pay for new medicines. In the letters, sent to Eli Lilly, Novo Nordisk, Pfizer and others, Trump insisted companies immediately lower what they charge Medicaid for existing drugs. Bloomberg Intelligence's Sam Fazeli breaks down the situation.",
    "url": "https://finnhub.io/api/news?id=64883fd0280805f67ba0b66f53c1526eda9f60f1790b2c7e924e88d651b8420c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754034632,
      "headline": "Trump Demands Pharma Companies to Lower US Prices",
      "id": 136165222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US President Donald Trump sent letters to 17 of the world's largest pharmaceutical companies demanding they charge the US what other countries pay for new medicines. In the letters, sent to Eli Lilly, Novo Nordisk, Pfizer and others, Trump insisted companies immediately lower what they charge Medicaid for existing drugs. Bloomberg Intelligence's Sam Fazeli breaks down the situation.",
      "url": "https://finnhub.io/api/news?id=64883fd0280805f67ba0b66f53c1526eda9f60f1790b2c7e924e88d651b8420c"
    }
  },
  {
    "ts": null,
    "headline": "Trump doubles down on Most Favored Nation plan to target drug prices",
    "summary": "Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.",
    "url": "https://finnhub.io/api/news?id=caa6f76ac187f7e7b18c00b896f616e50ea68bcbacfbe1ae0a2120c6d6cb861c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754008407,
      "headline": "Trump doubles down on Most Favored Nation plan to target drug prices",
      "id": 136160868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.",
      "url": "https://finnhub.io/api/news?id=caa6f76ac187f7e7b18c00b896f616e50ea68bcbacfbe1ae0a2120c6d6cb861c"
    }
  }
]